The Off-Label Use of Rituximab for the Management of Inflammatory Disorders: American University of Beirut Medical Center Experience

[1]  Manuel J. Amador-Patarroyo,et al.  Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. , 2012, Journal of autoimmunity.

[2]  Ana Lleo,et al.  Geoepidemiology, gender and autoimmune disease. , 2012, Autoimmunity reviews.

[3]  J. Tervaert.  Rituximab in ANCA-associated vasculitis: a revolution? , 2011 .

[4]  J. C. Cohen Tervaert.  Rituximab in ANCA-associated vasculitis: a revolution? , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  I. Sanz,et al.  Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning? , 2010, Discovery medicine.

[6]  P. Pillans,et al.  Off‐label use of rituximab in a tertiary Queensland hospital , 2010, Internal medicine journal.

[7]  E. Murray,et al.  Off-label use of rituximab in systemic lupus erythematosus: a systematic review , 2010, Clinical Rheumatology.

[8]  C. Gordon,et al.  Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. , 2010, Arthritis and rheumatism.

[9]  M. Ramos-Casals,et al.  Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases , 2009, Lupus.

[10]  A. Delannoy,et al.  Rituximab in auto‐immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study , 2009, Journal of internal medicine.

[11]  M. Ramos-Casals,et al.  A Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune Diseases , 2008, Medicine.

[12]  R. Fanin,et al.  Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long‐term follow‐up results , 2008, European journal of haematology.

[13]  M. Heffernan,et al.  Off‐label uses of rituximab in dermatology , 2007, Dermatologic therapy.

[14]  R. Ward,et al.  Off‐label use of medicines: consensus recommendations for evaluating appropriateness , 2006, The Medical journal of Australia.

[15]  J. Tuscano,et al.  Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. , 2005, The Journal of rheumatology.